|
Colorectal Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
In summary, our study demonstrated that CA3-AS1/miR-93/PTEN axis may play an important role in the regulation of colorectal cancer progression, which provides new insights for clinical treatment.
|
30415006 |
2019 |
|
Osteosarcoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Our data indicated that miR-93 was increased while TIMP2 was decreased in both OS cell lines and tissues.
|
31383784 |
2019 |
|
Osteosarcoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
AWPPH enhances FZD7-mediated activation of Wnt/β-catenin by sponging miR-93-3p to promote OS progression.
|
31092328 |
2019 |
|
Colorectal Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the results of the present study suggest that miR-93-5p serves a role in the development of MDR through downregulating CDKN1A gene expression in CRC.
|
28356951 |
2017 |
|
Osteosarcoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Transfection with miR-93 inhibitor significantly reduced the miR-93 levels and inhibited the proliferation of U2OS and MG63 osteosarcoma cells.
|
28565800 |
2017 |
|
Colorectal Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Herein, we have found that expression of miR-93 was lower in human colon cancer tissue and colorectal carcinoma cell lines compared with normal colon mucosa.
|
25371073 |
2015 |
|
Colorectal Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
We identified a panel of miR-409-3p, miR-7, and miR-93 that yielded high diagnostic accuracy in discriminating CRC from healthy group (AUC: 0.866 and 0.897 for training and validation dataset, respectively).
|
23456911 |
2015 |
|
Osteosarcoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
When anti-miR-93 was transfected into OS cell lines, PTEN expression was greatly increased, suggesting that PTEN might be a target of miR-93 in ES cells.
|
26243299 |
2015 |
|
Colorectal Carcinoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
Decreased translation of p21waf1 mRNA causes attenuated p53 signaling in some p53 wild-type tumors.
|
22510560 |
2012 |
|
Colorectal Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
We used microRNA arrays and observed that microRNA-93 had substantially different expression levels in early (recurrence within 12 months after surgery) and non-early relapse CRC patients.
|
22581829 |
2012 |
|
Osteosarcoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
Decreased translation of p21waf1 mRNA causes attenuated p53 signaling in some p53 wild-type tumors.
|
22510560 |
2012 |
|
Osteosarcoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Although further studies are needed to evaluate miRNA involvement in osteosarcoma progression, miR-93 overexpression seems to play an important role in osteosarcoma cell growth and invasion.
|
21959981 |
2012 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
We speculate that hsa_circRNA_104268/hsa-miR-214-3p/E2F2, hsa_circRNA_104168/hsa-miR-139-5p/HRAS, and hsa_circRNA_104769/hsa-miR-93-5p/JUN interaction pairs may play a vital role in HCC.
|
31222831 |
2020 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Re-expression of PDCD4 inversely correlated with the level of miR-93 and attenuated the miR-93-induced promotion of cell growth in HCC.
|
28592130 |
2019 |
|
Liver carcinoma
|
0.300 |
ModifyingMutation
|
disease |
RGD |
Re-expression of PDCD4 inversely correlated with the level of miR-93 and attenuated the miR-93-induced promotion of cell growth in HCC.
|
28592130 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Specifically, miR-93 has been reported to play a crucial role in colorectal, breast, pancreatic, lung cancer and hepatocellular carcinoma.
|
29760585 |
2018 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
We obtained 545 DEmiRNA-DEmRNA pairs that consisted of 258 DEmRNAs and 28 DEmiRNAs in HCC. mir-424, miR-93 and miR-3607 are three hub DEmiRNAs of the HCC-specific DEmiRNA-DEmRNA interaction network.
|
30186744 |
2018 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In summary, our work identified exosomal miR-93 as a novel biomarker for both diagnosis and prognosis in HCC.
|
29859935 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In addition, hsa-miR-93 was upregulated in <i>SNHG16</i>-overexpressed HCC cells to examine its effect on <i>SNHG16</i>-mediated cancer cell functional regulation in HCC.
|
30573973 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, these results suggested that miR-93-5p overexpression contributes to hepatoma development by inhibiting PPARGC1A.
|
29361788 |
2018 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Liver Cirrhosis, Alcoholic
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
miR-93 provides new insight into the molecular mechanisms of pathogenesis and progression in HCC and offer a potential therapeutic target for the treatment of HCC patients.
|
28748353 |
2017 |